Q1 - Q2 2025 BMC2 PCI Meetings

In a view from above, cropped so you cannot see their faces, a Black man and Black woman in business attire sit at a wooden table working on their laptops. Two white coffee mugs, a book, a phone, and headphones are also on the table.

Did you miss a meeting or need a refresher? Read summaries of our Q1 and Q2, 2025 BMC2 PCI Meetings.
 

The BMC2 PCI Coordinator Webinar was held on January 9th.

You can access a recording of the entire meeting and a PDF of the slide presentations on Nextcloud.

Highlights and Key Takeaways Include:

  • Dr. Eric Cantey, BMC2 PCI Associate Director, provided insights on intravascular imaging and non-invasive physiology. His session covered the reasons for using intravascular imaging, what optimized PCI entails, the differences between wire-based and non-wire-based physiology, and the devices relevant to the new "Non-Wire Based Physiological Assessment" field. He also explained the new Distal Reference Lumen Area (DRLA) and Minimal Stent Area (MSA) fields.  You can watch Dr. Cantey’s presentation via the YouTube link sent in the meeting follow-up email.
     
  • Mary Casey, BMC2 Project Manager, introduced the "PCI Abstractor Training Module." This online training is designed for new data coordinators and abstractors to ensure accurate data abstraction through field definition training. Others interested in a refresher can also take part upon request.
     
  • BMC2 PCI QI Leads, Kathleen Frazier and Amy Shirato, discussed the process of new field development, reviewed changes to the 2025 data collection, and explained the abstraction procedures for the new fields
  • Upcoming Meetings
  • New fields added:
    • “Cardiogenic Shock and/or Arrest” with child fields “lactate” and “pH”
    • “CT or Angiogram w/in 24 hours” with child field “Contrast Amount”
    • “Non-Wire Based Physiological Assessment”
    • “Distal Reference Lumen Area (DRLA)” and “Minimal Stent Area (MSA)” (child fields of “IVUS/OCT Post” field)
    • Medications: Bempedoic acid and Cholchicine
       
  • Fields retired:

Chart of retired PCI fields. Please contact the coordinating center for additional information if you have a barrier to seeing the image.

 

 

 

 


 

The BMC2 PCI Collaborative Webinar was held on February 20th. 

 A PDF of the webinar slides is available on NextCloud. The following presentations are available via the YouTube links sent in the meeting follow-up email:

  • “Colchicine in Contemporary Cardiac Practice: What Should an Interventionalist Do?”  Presented by Dr. Sanjit Jolly of McMaster University
  • “Enhancing Patient Safety Post-PCI: Leveraging Data, Education, & BMC2 to Address Shock” presented by Dr. Eric Cantey, Associate Director of BMC2 PCI
  • “In-Stent Restenosis in Clinical Practice: Incidence, Risk Factors, & Treatment Approaches” presented by Dr. Elias Dayoub of Michigan Medicine

 

The BMC2 PCI Coordinator Webinar was held on March 17, 2025.

Key Takeaways:

Dr. Eric Brandt, Director of Preventive Cardiology at Michigan Medicine presented on Lipid Management and Bempedoic Acid

  • If statins are not able to decrease LDL-C sufficiently and/or patients are intolerant alternate therapies are available.
  • Ezetimibe, PCSK9, and bempedoic acid are prescribed based on patients’ clinical and economic circumstances.

BMC2 PCI Quality Lead, Kathleen Frazier, presented on Risk Model Inclusion Criteria

  • The Observed rate (O) is the unadjusted outcome rate for the site for all PCI cases at the site included in the denominator.
  • The Expected rate (E) is the average of calibrated risk model predictions for all PCI cases at the site included in the denominator.
  • The risk model predictions are calibrated for the reporting period for patients in the registry meeting denominator requirements, the total of calibrated predictions is equal to the total number of observed events.
  • The overall collaborative rate is the total number of events (among cases meeting denominator requirements) divided by the total number of cases meeting denominator requirements).
  • https://www.bmc2.org/pci-risk-calculato

Cynthia Noack of MyMichigan and Kathleen Frazier presented on the Peer Review Process

  • Teams should assure abstractors have a clear understanding of the “Staged” and “Diagnostic Cath” definitions.
  • BMC2 PCI will provide more specific upload instructions and will update them each phase.
     

Amber Thompson of Corewell Health Trenton Hospital and Nichole Pardo of Corewell Health Beaumont Grosse Pointe Hospital presented on Guideline Medications at Discharge

  • If your facility is struggling with discharge medication performance consider assigning an appropriate team member to perform a final review of discharge medications prior to discharge (Pharmacist, RN, MLP, etc.)
     

The BMC2 PCI Coordinator Meeting was held at the Baronette Renaissance Hotel, in Novi, MI on May 9th, 2025. Photos are available on BMC2.org and you can view a PDF of the slide presentations on Nextcloud.

Highlights and key takeaways include:

  • Mollie Bodin, MA, our BMC2 PCI Program Manager, provided updates, including how to request MVC registry access to receive Cardiac Rehab Reports.
  • Stephanie Edwin, PharmD, and Amina Ammar, PharmD, presented “Optimizing Cardiovascular Outcomes with New Drug Therapies”
  • BMC2 PCI Associate Director, Eric Cantey, MD, presented “Introduction to Chronic Total Occlusion PCI”; “Shock in BMC2”; and “The BMC2 Shock Initiative”
  • Davy Hamilton, MD, from Michigan Medicine, presented “Post-PCI Risk Prediction” and “Cardiogenic Shock – The Next Step is a Team Effort”
  • Siddharth Gandhi, DO, from McLaren Northern, presented on “Interventional Clinical Perspectives on AMI-CS”
  • BMC2 PCI Quality Lead, Kathleen Frazier, BSN, RN, reviewed definitions and fields
  • Participants were assigned to breakout groups to discuss QI projects

 Resources:

  • The BMC2 PCI Risk Prediction Model is available on the resources page of bmc2.org.
     

The BMC2 PCI Collaborative Meeting was held at the Baronette Renaissance Hotel, in Novi, MI on May 10th, 2025. Photos of the meeting are available on bmc2.org. You can view a pdf of the slide presentations on Nextcloud.

 Highlights and key takeaways include:

    • Rasha Al-Lamee, MD from Imperial College, London, England, UK, virtually presented “Stable Angina in 2025, Role of Interventional Therapies after ORBITA1 and ORBITA2”
    • Ryan Madder, MD, provided a BMC2 PCI Advisory Committee Update
    • Brian Tell, one of our valued BMC2 PCI Patient Advisory Council (PAC) representatives, reported on recent PAC activities and presented his story
    • Mamas Mamas, MD from Keele University, Staffordshire, England, UK, virtually presented “PCI in a Patient with Cancer:  What is Different?”
    • Eric Cantey, MD, our BMC2 PCI Associate Program Director provided a BMC2 Data Review of unblinded data
    • Mollie Bodin, MA, our BMC2 PCI Program Manager, presented “Innovating Together:  Interactive Reporting”
    • Elizabeth Horn, our BMC2 Communications Specialist, presented “How to Communicate our Value & Impact Raising Awareness of BMC2”
    • Victor Strecher, PhD, MPH, from The University of Michigan, presented “On Purpose”
    • The BMC2 leadership team presented awards to eleven BMC2 PCI sites that showed Excellence in Cardiovascular Quality in 2024.  Congratulations to our awardees!
      • Corewell Health Beaumont Hospital Troy
      • Corewell Health Farmington Hills Hospital
      • Corewell Health Fred and Lena Meijer Heart Center, Grand Rapids
      • DMC Huron Valley Sinai Hospital
      • Henry Ford Hospital Detroit
      • Henry Ford Jackson Hospital
      • Henry Ford Warren Hospital
      • Holland Hospital
      • MyMichigan Health
      • Trinity Health Ann Arbor Hospital

Please remember that you cannot use BMC2 data to advertise your site.  

  • Resources
    • A new “BMC2 Proposal Intake Form” is available on BMC2.org, facilitating early input from co-authors and offering a collaborative statement of work and a comprehensive resource guide. 
    • For media training, social media assistance, or help sharing your news, email bmc2.info@umich.edu.
  • Calls to action

​​​​Flyers and postcards were distributed to recruit new members for the BMC2 PCI Patient Advisory Council (PAC). Information can also be accessed by visiting the Patient Advisory Council page of bmc2.org. 


The BMC2 PCI 2026 P4P Goal Meeting was held on June 10, 2025, where the goals recommended by the PCI Advisory Committee were reviewed.  A PDF copy of the slide deck is available on NextCloud.

Participants supported the following P4P Goals:

  • 2026 Pay for Performance (P4P) Goals
    • Cardiac Rehab
      • Site performance ≥ 40% or absolute increase of ≥ 5 points in the measurement period (CY2025) compared with the immediate prior 12-month period (CY2024). Scored in 2026; = 10 points
      • Site performance ≥ 37% or absolute increase of ≥ 3 points in the measurement period (CY2025) compared with the immediate prior 12-month period (CY2024). Scored in 2026; = 5 points
  • Continue with the Outcomes and Process Composite; inclusive of risk-adjusted mortality, risk-adjusted AKI, risk-adjusted bleeding, guideline medication prescription at discharge (aspirin, statin, P2Y12), and referral to cardiac rehab.  Points are awarded on a 25-point scale based on performance for each of the elements.  For each of the risk-adjusted outcome measures, 5 points are awarded A/P <1, 3 points A/P 1-1.5, and 0 points A/P >1.5.
  • Use of IVUS/OCT for stent optimization
  • Keep and increase the target to >60% in EITHER all cases OR >75% in cases involving the left main coronary artery, in-stent restenosis, or stent thrombosis (10 points)
  • >10 percentage points absolute increase in all cases from Q4 YTD 2024 (5 points)

Participants supported the following goals for 2026 Value Based Reimbursement (VBR):

  • Keep Increase the appropriateness of PCI therapy, based on the BMC2 ongoing peer review process.
  • Keep Improve the overall intervention quality as assessed in the BMC2 ongoing peer review process.
  • Keep Submit internal peer review cases and attest to discussing the cross-site review comments and internal review cases with colleagues.

P4P and VBR goals will be reviewed by Blue Cross Blue Shield of Michigan. We will notify you when we receive final approval.

 

Peer Review Updates

2024B Peer Review will focus on Shock. Sites will upload 3 cases; Physicians will review 6 external cases, and for the internal review, they will review the 3 cases they uploaded from their site.

Timeline:

  • Sites must upload cases by 8/4/25
  • Cross-site External Peer Review is 8/25/25 – 9/22/25
  • Internal Review is due by 10/27/25